Dare Bioscience, Inc. (DARE) stock
Close on Nov 11, 2026Market cap $10.61MP/E –Yield –
Dare Bioscience, Inc. reported revenue of $1.37M for the twelve months to Jun 30, 2026. Free cash flow was -$11.76M. At the latest close the market valued the company at $10.61M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.61M
- P/E ratio
- –
- Price to sales
- 7.77
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -110.77%
Fundamentals
- Revenue
- $1.37M
- Net income
- -$10.99M
- EPS, diluted
- -$0.79
- Free cash flow
- -$11.76M
- Book value per share
- -$0.04
- Diluted shares
- 15M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $0.69
- Open
- $0.71
- Day's range
- $0.69 – $0.71
- Volume
- 97,946
- Average volume (20 days)
- 151,892
- Beta (5 years)
- 1.40
- 52-week range
- $0.61 – $3.78
- RSI (14 days)
- 48.2
- Volatility (1 year)
- 105.3%
- Relative volume
- 0.24×
- WACC
- 11.9%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DARE | S&P 500 | Difference | DARE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.3% | -2.4% | −7.8 pts | ||
| 3 months | -51.8% | -1.2% | −50.6 pts | ||
| Year to date | -64.0% | +12.3% | −76.3 pts | ||
| 1 year | -64.2% | +12.4% | −76.7 pts | ||
| 3 years | -82.5% | +78.8% | −161.3 pts | -44.0% | +21.4% |
| 5 years | -96.5% | +75.2% | −171.7 pts | -48.8% | +11.9% |
| 10 years | -99.3% | +311.1% | −410.4 pts | -39.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Dare Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Results
- Update
- Update
About Dare Bioscience
Pharmaceutical Preparations
Daré Bioscience, Inc. is a biopharmaceutical company that develops and commercializes health products specifically designed for women. The company targets therapeutic areas including contraception, sexual health, vaginal health, pelvic pain, fertility, and menopause. Its commercial portfolio features XACIATO, an FDA-approved prescription vaginal gel licensed to Organon for treating bacterial vaginosis, as well as DARE to PLAY Sildenafil Cream, which is compounded under Section 503B regulations for female sexual arousal disorder. Additionally, Daré offers non-prescription consumer wellness items, including Flora Sync LF5 under the DARE to RESTORE vaginal probiotic line. The company serves female patients, healthcare providers, and consumers through telehealth services, dispensing pharmacies, and commercial partners.
Company profile, executives and historyDare Bioscience stock: common questions
What is Dare Bioscience's stock price?
DARE closed at $0.69 on Nov 11, 2026, up 0.29% on the day. Over the past 52 weeks it traded between $0.61 and $3.78.
What is Dare Bioscience's market cap?
Dare Bioscience was worth $10.61M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DARE's P/E ratio?
Dare Bioscience lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.79), so it has no meaningful P/E ratio.
How much revenue does Dare Bioscience make?
Dare Bioscience reported revenue of $1.37M for the twelve months to Jun 30, 2026.
Does Dare Bioscience pay a dividend?
No. Dare Bioscience has not paid a cash dividend over the last twelve months.
When does Dare Bioscience report earnings next?
Dare Bioscience is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has DARE stock performed over the past year?
Including dividends, DARE returned -64.2% over the past year, against +12.4% for the S&P 500.
How many DARE shares are sold short?
1M shares were sold short at the latest FINRA report, 7.12% of the float, or 6.1 days of average trading volume.
Who are Dare Bioscience's competitors?
Companies most similar to Dare Bioscience by business, industry and size include TXMD, LPCN, SXTP, EVFM, VTGN.
See a number that looks wrong?